Skip to main content

Treatment as Prevention of HIV Transmission


July 27, 2012 (Washington, DC) — "The paradigm for use of antiretroviral therapy has shifted; treatment and prevention have converged," a panel from the International Association of Physicians in AIDS Care (IAPAC) announced here at AIDS 2012: XIX International AIDS Conference.
The foundation of the approach requires treatment as soon as HIV-positivity is established and the use of preexposure prophylaxis, said José M. Zuniga, PhD, MPH, a member of the IAPAC from Washington, DC.
"Successful treatment as prevention will require higher levels of HIV testing, enhanced linkage to and retention in care, access to quality treatment, adherence support, and new ways to monitor coverage and treatment," reports the IAPAC panel in its consensus statement.
Julio Montaner, MD, director of the British Columbia Center for Excellence in HIV/AIDS, chair in AIDS research and head of division of AIDS at the University of British Columbia in Vancouver, Canada, and past-president of the International AIDS Society, told meeting attendees that this should put to rest any discussion: "Treating the individual helps them but also helps reduce transmission of the virus.... Early treatment reduces morbidity, mortality, and transmission."
"It is no longer a matter of whether we want to treat or if we can; now we know we have to," Dr. Montaner explained.
"I think we can curb the AIDS epidemic," copanelist Kenneth Brayer, MD, professor of medicine and of epidemiology at Brown University in Providence, Rhode Island, told Medscape Medical News. "There are compelling data that these efforts work."
"We need to decriminalize treatment," Dr. Montaner added. Efforts at HIV detection and treatment directed at prison populations and sex workers are well underway in Canada, he said. Convincing politicians that early access to affordable treatment decreases morbidity and mortality and reduces HIV transmission is something that needs to be tackled, he noted.
"Our challenge is how to convey hope...that ending AIDS is more than a cliché," Dr. Zuniga said.
The speakers have disclosed no relevant financial relationships.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

FDA Decision Delayed for Truvada in HIV PrEP

June 11, 2012 — The US Food and Drug Administration (FDA) has delayed its decision on allowing the use of tenofovir disoproxil fumarate/emtricitabine ( Truvada , Gilead) as preexposure prophylaxis (PrEP) so that the proposed risk evaluation and mitigation strategy (REMS) can be reviewed. In early May, the FDA's Antiviral Drugs Advisory Committee  strongly backed  approval of the first-ever drug for the prevention of sexually acquired HIV-1 infection. However, concerns by the panel at the time included that people may neglect condom use if they feel they are protected by PrEP. Panelists were also concerned that uninfected people taking PrEP who become infected with HIV may not switch to a 3-drug regimen as recommended. According to the company, the FDA has postponed the target date to September 14 so it can review Gilead's REMS plan to help ensure that patients will not misuse the drug. The committee's recommendation for supplemental approval of tenofovir/emtricit...
Post a Comment
Read more

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...
Post a Comment
Read more